Genflow Biosciences Plc Enters Strategic CDAs with Leading Animal Health Companies to Propel Longevity Gene Therapy Platform

Reuters2025-09-15

<a href="https://laohu8.com/S/GENFF">Genflow Biosciences Plc</a> Enters Strategic CDAs with Leading Animal Health Companies to Propel Longevity Gene Therapy Platform

Genflow Biosciences Plc, the only publicly listed longevity company in Europe, has signed two Confidential Disclosure Agreements with leading animal health companies. This strategic move facilitates the exchange of data and initiates discussions on potential collaborations. The agreements are a significant step in Genflow's strategy to leverage its proprietary SIRT6-centenarian gene therapy platform for both human and animal health. As part of its ongoing GF-1004 Dog Aging study, which has reported no adverse events, these agreements provide a framework for evaluating partnership opportunities aimed at extending healthspan and improving the quality of life in companion animals, a rapidly growing market segment. This collaboration is expected to accelerate the path to commercialization, unlocking global scale and regulatory expertise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073058) on September 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2567219391?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567219391","market":"us","top_or_hot":-1,"title":"Genflow Biosciences Plc Enters Strategic CDAs with Leading Animal Health Companies to Propel Longevity Gene Therapy Platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GENFF\">Genflow Biosciences Plc</a> Enters Strategic CDAs with Leading Animal Health Companies to Propel Longevity Gene Therapy Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Genflow Biosciences Plc, the only publicly listed longevity company in Europe, has signed two Confidential Disclosure Agreements with leading animal health companies. This strategic move facilitates the exchange of data and initiates discussions on potential collaborations. The agreements are a significant step in Genflow's strategy to leverage its proprietary SIRT6-centenarian gene therapy platform for both human and animal health. As part of its ongoing GF-1004 Dog Aging study, which has reported no adverse events, these agreements provide a framework for evaluating partnership opportunities aimed at extending healthspan and improving the quality of life in companion animals, a rapidly growing market segment. This collaboration is expected to accelerate the path to commercialization, unlocking global scale and regulatory expertise.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073058) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genflow Biosciences Plc Enters Strategic CDAs with Leading Animal Health Companies to Propel Longevity Gene Therapy Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenflow Biosciences Plc Enters Strategic CDAs with Leading Animal Health Companies to Propel Longevity Gene Therapy Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-15 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GENFF\">Genflow Biosciences Plc</a> Enters Strategic CDAs with Leading Animal Health Companies to Propel Longevity Gene Therapy Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Genflow Biosciences Plc, the only publicly listed longevity company in Europe, has signed two Confidential Disclosure Agreements with leading animal health companies. This strategic move facilitates the exchange of data and initiates discussions on potential collaborations. The agreements are a significant step in Genflow's strategy to leverage its proprietary SIRT6-centenarian gene therapy platform for both human and animal health. As part of its ongoing GF-1004 Dog Aging study, which has reported no adverse events, these agreements provide a framework for evaluating partnership opportunities aimed at extending healthspan and improving the quality of life in companion animals, a rapidly growing market segment. This collaboration is expected to accelerate the path to commercialization, unlocking global scale and regulatory expertise.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073058) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK5083","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL4KHpnB:1","article_id":"2567219391","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567219391","pubTimestamp":1757916022,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Genflow Biosciences Plc, the only publicly listed longevity company in Europe, has signed two Confidential Disclosure Agreements with leading animal health companies. This strategic move facilitates the exchange of data and initiates discussions on potential collaborations. The agreements are a significant step in Genflow's strategy to leverage its proprietary SIRT6-centenarian gene therapy platform for both human and animal health. As part of its ongoing GF-1004 Dog Aging study, which has reported no adverse events, these agreements provide a framework for evaluating partnership opportunities aimed at extending healthspan and improving the quality of life in companion animals, a rapidly growing market segment. This collaboration is expected to accelerate the path to commercialization, unlocking global scale and regulatory expertise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK5083":"生物科技","GENF.UK":"GENFLOW BIOSCIENCES PLC"},"translate_title":"Genflow Biosciences Plc与领先的动物保健公司达成战略CDA，以推动长寿基因治疗平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GENF.UK":0.9},"content_text":"Genflow Biosciences Plc Enters Strategic CDAs with Leading Animal Health Companies to Propel Longevity Gene Therapy Platform\n    \n\n        Genflow Biosciences Plc, the only publicly listed longevity company in Europe, has signed two Confidential Disclosure Agreements with leading animal health companies. This strategic move facilitates the exchange of data and initiates discussions on potential collaborations. The agreements are a significant step in Genflow's strategy to leverage its proprietary SIRT6-centenarian gene therapy platform for both human and animal health. As part of its ongoing GF-1004 Dog Aging study, which has reported no adverse events, these agreements provide a framework for evaluating partnership opportunities aimed at extending healthspan and improving the quality of life in companion animals, a rapidly growing market segment. This collaboration is expected to accelerate the path to commercialization, unlocking global scale and regulatory expertise.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genflow Biosciences plc published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073058) on September 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2567219391","isCrawlerRequest":true}